Antiviral agents encompass a diverse range of pharmaceutical weapons in the ongoing battle against viral infections. Nucleoside analogs, exemplified by acyclovir and tenofovir, disrupt the viral life cycle by interfering with DNA or RNA synthesis, impeding the replication of viruses like herpes and HIV. Protease inhibitors, including ritonavir and lopinavir, play a crucial role in managing retroviruses like HIV by inhibiting the maturation of viral proteins. Neuraminidase inhibitors, such as oseltamivir, prove instrumental in treating influenza by preventing the release of new virus particles. Immunomodulators, like interferons, bolster the host's immune response, aiding in the identification and elimination of virus-infected cells. Entry inhibitors, like maraviroc, block the initial stages of viral infection by preventing the virus from entering host cells. Additionally, the cutting-edge RNA interference (RNAi)-based therapies target viral genes, utilizing the cell's natural defense mechanisms to silence specific viral genetic material, presenting a promising avenue for innovative antiviral interventions.